Back to search

National and Kapodistrian University of Athens

Χορήγηση αντιβιοτικών σε υποψία λοίμωξης καθοδηγούμενη από βιοδείκτες

Abstract

dc:description

Background. Sepsis guidelines suggest immediate start of resuscitation for patients with quick Sequential Organ Failure Assessment (qSOFA) 2 or 3. However, the interpretation of qSOFA 1 remains controversial. We investigated if measurements of soluble urokinase plasminogen activator receptor (suPAR) may improve risk detection when qSOFA is 1. Methods. The study had two parts. At the first part, the combination of suPAR with qSOFA was analyzed in a prospective cohort for early risk detection. At the second part, the double-blind, randomized controlled trial (RCT) SUPERIOR evaluated the efficacy of the suPAR-guided medical intervention. SUPERIOR took place between November 2018 and December 2020. Multivariate stepwise Cox regression was used for the prospective cohort, while univariate and multivariate logistic regression were used for the RCT. Consecutive admissions at the emergency department (ED) with suspected infection, qSOFA 1 and suPAR≥12 ng/mL were allocated to single infusion of placebo or meropenem. The primary endpoint was early deterioration, defined as at least one-point increase of admission Sequential Organ Failure Assessment (SOFA) score the first 24 hours.Results. Most of mortality risk was for patients with qSOFA 2 and 3. Taking the hazard ratio (HR) for death of patients with qSOFA=1 and suPAR<12 ng/mL as reference, the HR of qSOFA=1 and suPAR≥12ng/mL for 28-day mortality was 2.98 (95% CI 2.11-3.96).The prospective RCT was prematurely ended due to pandemia-related ED re-allocations, with 91 patients enrolled: 47 in the placebo and 44 in the meropenem arm. The primary endpoint was met in 40.4% (n= 19) and 15.9% (n= 7), respectively (difference 24.5% [5.9-40.8]; odds ratio 0.28 [0.10-0.76]). One post-hoc analysis showed significant median changes of SOFA score after 72 and 96 hours equal to 0 and -1 respectively. Conclusions. Combining qSOFA 1 with the biomarker suPAR improves its prognostic performance for unfavorable outcome and may help decision for earlier treatment.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Adami, Maria-Evangelia
  • Αδάμη, Μαρία-Ευαγγελία

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/56700

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Adami, Maria-Evangelia; Αδάμη, Μαρία-Ευαγγελία. Χορήγηση αντιβιοτικών σε υποψία λοίμωξης καθοδηγούμενη από βιοδείκτες. National and Kapodistrian University of Athens, 2024. http://hdl.handle.net/10442/hedi/56700